PLCO
Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial: prostate-cancer screening component
N = 76,693NCT00002540
- Population
- Men aged 55-74 years at entry (full text of the 2009 report), randomised at 10 US study centres from 1993 through 2001.
- Design
- Randomised screening trial at 10 US study centres (men randomised 1993 through 2001). Men in the screening group were offered annual PSA testing for 6 years and digital rectal examination for 4 years; participants and their health care providers received the results and decided on follow-up evaluation. The control group received usual care, which sometimes included screening.
- Primary endpoint
- Prostate cancer mortality
- Arms
- Annual screening (experimental, n = 38,343): Annual PSA testing for 6 years and digital rectal examination for 4 years
- Usual care (control, n = 38,350): Usual care, which sometimes included screening
- People
- Andriole GL, PLCO Project Team
Δ Men with any PSA testing during the trial+13 points
Show the numbers
| Endpoint | Analysis | Annual screening | Usual care | Effect |
|---|---|---|---|---|
| Men with any PSA testing during the trialMen randomised (38,340 intervention arm and 38,343 control arm in the 2017 report)Estimated proportion of men in the arm who received any PSA testing during the trial, as estimated in the 2017 extended-follow-up report. | long term-updatemedian follow-up 14.8 yearsPinsky 2017 | 99% | 86% | Both figures are estimates stated in the abstract. Estimated yearly screening-phase PSA testing was 84% in the intervention arm and 46% in the control arm. In the same report, deaths from prostate cancer were 255 (intervention) and 244 (control), rate ratio 1.04 (95% CI 0.87-1.24); median follow-up 14.8 years (intervention) and 14.7 years (control). Arm sizes in the 2017 report differ slightly from the 2009 report's. |
| Endpoint | Analysis | Annual screening | Usual care | Effect |
|---|---|---|---|---|
| Men with any PSA testing during the trialMen randomised (38,340 intervention arm and 38,343 control arm in the 2017 report)Estimated proportion of men in the arm who received any PSA testing during the trial, as estimated in the 2017 extended-follow-up report. | long term-updatemedian follow-up 14.8 yearsPinsky 2017 | 99% | 86% | Both figures are estimates stated in the abstract. Estimated yearly screening-phase PSA testing was 84% in the intervention arm and 46% in the control arm. In the same report, deaths from prostate cancer were 255 (intervention) and 244 (control), rate ratio 1.04 (95% CI 0.87-1.24); median follow-up 14.8 years (intervention) and 14.7 years (control). Arm sizes in the 2017 report differ slightly from the 2009 report's. |
Appears in
Sources
Andriole GL, Crawford ED, Grubb RL 3rd, Buys SS, Chia D, Church TR, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med. 2009;360(13):1310-9.
Pinsky PF, Prorok PC, Yu K, Kramer BS, Black A, Gohagan JK, et al. Extended mortality results for prostate cancer screening in the PLCO trial with median follow-up of 15 years. Cancer. 2017;123(4):592-599.